U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

NRAS Exon 3 Mutation

MedGen UID:
1612683
•Concept ID:
C4526002
•
Cell or Molecular Dysfunction
Synonyms: N-RAS Exon 3 Mutation; Neuroblastoma RAS Viral Oncogene Homolog Exon 3 Mutation; NRAS Exon 3 Gene Mutation

Definition

A molecular genetic abnormality indicating the presence of a mutation in exon 3 of the NRAS gene. [from NCI]

Professional guidelines

PubMed

Dedifferentiated and Undifferentiated Melanomas: Report of 35 New Cases With Literature Review and Proposal of Diagnostic Criteria.
Agaimy A, Stoehr R, Hornung A, Popp J, Erdmann M, Heinzerling L, Hartmann A
Am J Surg Pathol 2021 Feb 1;45(2):240-254. doi: 10.1097/PAS.0000000000001645. PMID: 33428337
The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines.
Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK
Gastric Cancer 2016 Jan;19(1):3-14. Epub 2015 Aug 15 doi: 10.1007/s10120-015-0526-8. PMID: 26276366Free PMC Article
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M
Acta Oncol 2014 Jul;53(7):852-64. Epub 2014 Mar 25 doi: 10.3109/0284186X.2014.895036. PMID: 24666267

Recent clinical studies

Etiology

Prevalence and patterns of mutations in RAS/RAF/MEK/ERK/MAPK signaling pathway in colorectal cancer in North Africa.
Jafari M, Laraqui A, Baba W, Benmokhtar S, Zaitouni SE, Ali AA, Bounaim A, Moujahid M, Tanz R, Mahfoud T, Sbitti Y, Annaz HE, Abi R, Tagajdid MR, Kochri SE, Lahlou IA, Hsaini HE, Belayachi L, Benjouad A, Ichou M, En-Nya A, Ennibi K
BMC Cancer 2022 Nov 7;22(1):1142. doi: 10.1186/s12885-022-10235-w. PMID: 36344948Free PMC Article
Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.
Ishikawa Y, Kawashima N, Atsuta Y, Sugiura I, Sawa M, Dobashi N, Yokoyama H, Doki N, Tomita A, Kiguchi T, Koh S, Kanamori H, Iriyama N, Kohno A, Moriuchi Y, Asada N, Hirano D, Togitani K, Sakura T, Hagihara M, Tomikawa T, Yokoyama Y, Asou N, Ohtake S, Matsumura I, Miyazaki Y, Naoe T, Kiyoi H
Blood Adv 2020 Jan 14;4(1):66-75. doi: 10.1182/bloodadvances.2019000709. PMID: 31899799Free PMC Article
RAS proto-oncogene in medullary thyroid carcinoma.
Moura MM, Cavaco BM, Leite V
Endocr Relat Cancer 2015 Oct;22(5):R235-52. doi: 10.1530/ERC-15-0070. PMID: 26285815
Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
Van Cutsem E, Lenz HJ, Köhne CH, Heinemann V, Tejpar S, Melezínek I, Beier F, Stroh C, Rougier P, van Krieken JH, Ciardiello F
J Clin Oncol 2015 Mar 1;33(7):692-700. Epub 2015 Jan 20 doi: 10.1200/JCO.2014.59.4812. PMID: 25605843
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD
N Engl J Med 2013 Sep 12;369(11):1023-34. doi: 10.1056/NEJMoa1305275. PMID: 24024839

Diagnosis

KRAS, NRAS, BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients.
Mirzapoor Abbasabadi Z, Hamedi Asl D, Rahmani B, Shahbadori R, Karami S, Peymani A, Taghizadeh S, Samiee Rad F
J Clin Lab Anal 2023 Mar;37(5):e24868. Epub 2023 Mar 17 doi: 10.1002/jcla.24868. PMID: 36930789Free PMC Article
BRAF, NRAS, KIT, TERT, GNAQ/GNA11 Mutation Profile and Histomorphological Analysis of Anorectal Melanomas: A Clinicopathologic Study.
Taskin OC, Sari SO, Yilmaz I, Hurdogan O, Keskin M, Buyukbabani N, Gulluoglu M
Turk Patoloji Derg 2023;39(1):23-30. doi: 10.5146/tjpath.2022.01576. PMID: 35642348Free PMC Article
Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.
Ishikawa Y, Kawashima N, Atsuta Y, Sugiura I, Sawa M, Dobashi N, Yokoyama H, Doki N, Tomita A, Kiguchi T, Koh S, Kanamori H, Iriyama N, Kohno A, Moriuchi Y, Asada N, Hirano D, Togitani K, Sakura T, Hagihara M, Tomikawa T, Yokoyama Y, Asou N, Ohtake S, Matsumura I, Miyazaki Y, Naoe T, Kiyoi H
Blood Adv 2020 Jan 14;4(1):66-75. doi: 10.1182/bloodadvances.2019000709. PMID: 31899799Free PMC Article
The State of the Art in Colorectal Cancer Molecular Biomarker Testing.
Pillai RK, Lopategui JR, Dhall D, Guindi M, Slavin T, Lofton-Day CE, Patterson SD
Adv Anat Pathol 2016 Mar;23(2):92-103. doi: 10.1097/PAP.0000000000000107. PMID: 26849815Free PMC Article
The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines.
Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK
Gastric Cancer 2016 Jan;19(1):3-14. Epub 2015 Aug 15 doi: 10.1007/s10120-015-0526-8. PMID: 26276366Free PMC Article

Therapy

The State of the Art in Colorectal Cancer Molecular Biomarker Testing.
Pillai RK, Lopategui JR, Dhall D, Guindi M, Slavin T, Lofton-Day CE, Patterson SD
Adv Anat Pathol 2016 Mar;23(2):92-103. doi: 10.1097/PAP.0000000000000107. PMID: 26849815Free PMC Article
RAS proto-oncogene in medullary thyroid carcinoma.
Moura MM, Cavaco BM, Leite V
Endocr Relat Cancer 2015 Oct;22(5):R235-52. doi: 10.1530/ERC-15-0070. PMID: 26285815
Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer.
Dienstmann R, Salazar R, Tabernero J
Am Soc Clin Oncol Educ Book 2015:e149-56. doi: 10.14694/EdBook_AM.2015.35.e149. PMID: 25993166
Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
Van Cutsem E, Lenz HJ, Köhne CH, Heinemann V, Tejpar S, Melezínek I, Beier F, Stroh C, Rougier P, van Krieken JH, Ciardiello F
J Clin Oncol 2015 Mar 1;33(7):692-700. Epub 2015 Jan 20 doi: 10.1200/JCO.2014.59.4812. PMID: 25605843
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD
N Engl J Med 2013 Sep 12;369(11):1023-34. doi: 10.1056/NEJMoa1305275. PMID: 24024839

Prognosis

Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.
Ishikawa Y, Kawashima N, Atsuta Y, Sugiura I, Sawa M, Dobashi N, Yokoyama H, Doki N, Tomita A, Kiguchi T, Koh S, Kanamori H, Iriyama N, Kohno A, Moriuchi Y, Asada N, Hirano D, Togitani K, Sakura T, Hagihara M, Tomikawa T, Yokoyama Y, Asou N, Ohtake S, Matsumura I, Miyazaki Y, Naoe T, Kiyoi H
Blood Adv 2020 Jan 14;4(1):66-75. doi: 10.1182/bloodadvances.2019000709. PMID: 31899799Free PMC Article
The State of the Art in Colorectal Cancer Molecular Biomarker Testing.
Pillai RK, Lopategui JR, Dhall D, Guindi M, Slavin T, Lofton-Day CE, Patterson SD
Adv Anat Pathol 2016 Mar;23(2):92-103. doi: 10.1097/PAP.0000000000000107. PMID: 26849815Free PMC Article
RAS proto-oncogene in medullary thyroid carcinoma.
Moura MM, Cavaco BM, Leite V
Endocr Relat Cancer 2015 Oct;22(5):R235-52. doi: 10.1530/ERC-15-0070. PMID: 26285815
Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer.
Dienstmann R, Salazar R, Tabernero J
Am Soc Clin Oncol Educ Book 2015:e149-56. doi: 10.14694/EdBook_AM.2015.35.e149. PMID: 25993166
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD
N Engl J Med 2013 Sep 12;369(11):1023-34. doi: 10.1056/NEJMoa1305275. PMID: 24024839

Clinical prediction guides

KRAS, NRAS, BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients.
Mirzapoor Abbasabadi Z, Hamedi Asl D, Rahmani B, Shahbadori R, Karami S, Peymani A, Taghizadeh S, Samiee Rad F
J Clin Lab Anal 2023 Mar;37(5):e24868. Epub 2023 Mar 17 doi: 10.1002/jcla.24868. PMID: 36930789Free PMC Article
The State of the Art in Colorectal Cancer Molecular Biomarker Testing.
Pillai RK, Lopategui JR, Dhall D, Guindi M, Slavin T, Lofton-Day CE, Patterson SD
Adv Anat Pathol 2016 Mar;23(2):92-103. doi: 10.1097/PAP.0000000000000107. PMID: 26849815Free PMC Article
RAS Mutations Beyond KRAS Exon 2: A Review and Discussion of Clinical Trial Data.
Cannon TL, Kokon MA, Shafqat S, Deeken JF
Curr Treat Options Oncol 2015 Jul;16(7):33. doi: 10.1007/s11864-015-0350-8. PMID: 26050230
Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer.
Dienstmann R, Salazar R, Tabernero J
Am Soc Clin Oncol Educ Book 2015:e149-56. doi: 10.14694/EdBook_AM.2015.35.e149. PMID: 25993166
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD
N Engl J Med 2013 Sep 12;369(11):1023-34. doi: 10.1056/NEJMoa1305275. PMID: 24024839

Recent systematic reviews

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
Chan DLH, Segelov E, Wong RS, Smith A, Herbertson RA, Li BT, Tebbutt N, Price T, Pavlakis N
Cochrane Database Syst Rev 2017 Jun 27;6(6):CD007047. doi: 10.1002/14651858.CD007047.pub2. PMID: 28654140Free PMC Article
Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015.
Allegra CJ, Rumble RB, Hamilton SR, Mangu PB, Roach N, Hantel A, Schilsky RL
J Clin Oncol 2016 Jan 10;34(2):179-85. Epub 2015 Oct 5 doi: 10.1200/JCO.2015.63.9674. PMID: 26438111
Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.
Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS
Ann Oncol 2015 Jan;26(1):13-21. Epub 2014 Aug 12 doi: 10.1093/annonc/mdu378. PMID: 25115304
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M
Acta Oncol 2014 Jul;53(7):852-64. Epub 2014 Mar 25 doi: 10.3109/0284186X.2014.895036. PMID: 24666267

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...